Abstract
We report the case of two patients with newly diagnosed primary hyperparathyroidism: a 40-year-old woman during pregnancy and a 60-year-old man with initial hypercalcaemic crisis. In the first case, a bilateral neck exploration with parathyroidectomy during the second trimester of pregnancy was unsuccessful and the patient remained hypercalcaemic. Postpartum imaging assessment with technetium (99mTc)-sestamibi scintigraphy could not supply conclusive diagnostic results. The use of 18F-fluorocholine (FCH) positron emission tomography (PET)/CT provided the accurate localisation of an ectopic parathyroid adenoma in the anterior mediastinum which was successfully resected by a thoracoscopic approach. In the second case, 99mTc-sestamibi scintigraphy was inconclusive as well and FCH-PET/CT localised an ectopic parathyroid adenoma in the mediastinum and thus bilateral neck exploration could be spared. Both patients had surgical cure of their disease.
Keywords: calcium and bone, radiology, cardiothoracic surgery, otolaryngology / ent
Background
Primary hyperparathyroidism (pHPT) is characterised by the autonomous secretion of parathyroid hormone (PTH) by one or more parathyroid glands. The most frequent cause of pHPT, occurring in 80%–90% of patients, is a benign solitary parathyroid adenoma.1 Ectopic localisation is found in up to 22%, the prevalence is even higher in patients with redo surgeries.2 3 Surgery is the only definitive cure for pHPT and is indicated in all symptomatic patients, as well as in a defined subgroup of so-called ‘asymptomatic’ patients.4 The goals of parathyroid surgery are to remove all hyperfunctioning tissue and to preserve normal parathyroid glands. In the past, the standard surgical approach included bilateral cervical exploration. Nowadays, focused approaches have currently gained more acceptance as they are safe and effective alternatives. However, the essential prerequisite for focused parathyroidectomy is proper localisation of all autonomic tissue, including detection of ectopic and supernumerous parathyroid lesions. The most commonly used imaging modalities for this purpose are ultrasound of the neck and parathyroid scintigraphy with technetium (99mTc)-sestamibi (most often combined with single-photon emission CT (SPECT)/CT).5 However, sensitivity of ultrasound and scintigraphy is limited in several situations. Recent patient level studies have shown good accuracy and equal or even superior detection using 18F-fluorocholine PET/CT (FCH-PET/CT) compared with commonly used imaging using 99mTc-sestamibi scintigraphy or ultrasound.6–9In this publication, we report two cases of patients with pHPT due to an ectopic parathyroid adenoma in the mediastinum and negative/equivocal conventional imaging procedures (neck ultrasound and 99mTc-sestamibi scintigraphy/SPECT/CT). Both had successful localisation of the mediastinal adenoma by FCH-PET/CT and subsequently surgical cure of the pHPT.
Case presentation
Case presentation 1
A 40-year-old female patient presented in the eighth week of gestation with nausea and extensive hyperemesis gravidarum. In the clinical examination, she was hypotensive, had a reduced skin turgor and dry mucous membranes. Laboratory analysis revealed elevated serum calcium level and PTH level (albumin-corrected serum calcium level 3.04 mmol/L [reference range 2.15–2.50 mmol/L], PTH level 120 pg/mL [reference range 15–65 pg/mL]) and a low serum phosphate level of 0.81 mmol/L (reference range 0.87–1.45 mmol/L). Genetic testing was negative for a Multiple Endocrine Neoplasia Type 1 (MEN-1).
Due to persistent, symptomatic hypercalcaemia and associated maternal and fetal risks, the patient underwent bilateral neck exploration during the second trimester. Preoperative localisation diagnostic with ultrasound was inconclusive; scintigraphy could not be performed because of pregnancy.
Biopsies of all four resected parathyroid glands showed no evidence of adenomas or malignancy. After an uncomplicated caesarean section and after cessation of breast feeding, hypercalcaemia persisted. Imaging studies were complemented by 99mTc-sestamibi scintigraphy/SPECT/CT which suspected the presence of an ectopic parathyroid adenoma in the right middle mediastinum nearby residual thymic tissue. Further investigation with FCH-PET/CT confirmed the presence of a 6 mm parathyroid adenoma (figure 1). The patient underwent thoracoscopic thymic resection (figure 2)and the presence of an intrathymic parathyroid adenoma was verified by histological examination.
Figure 1.
18F-fluorocholine PET/CT in patient 1. Diagnostic-enhanced contrast CT (left) and PET (right) showing the adenoma located in the right middle mediastinum (arrow). PET, positron emission tomography.
Figure 2.

Intraoperative, thoracoscopic situation in patient 1: right pleural cavity, lateral view. 1: parathyroid adenoma enclosed by hyperplastic thymus (subpleurally located); 2: superior vena cava and phrenic nerve; 3: pericardium (right ventricle); 4: superior pulmonal lobe (collapsed); 5: right internal mammary artery/vein.
Case presentation 2
A 60-year-old patient presented with bilateral muscle weakness, paraesthesia, anorexia and a weight loss of 24 kg in the past year. Laboratory analysis confirmed pHPT by clearly elevated serum calcium level and PTH level (albumin-corrected serum calcium level 3.60 mmol/L [reference range 2.20–2.55 mmol/L], PTH level 349 pg/mL [reference range 15–65 pg/mL]) and a low serum phosphate level of 0.44 mmol/L (reference range 0.87–1.45 mmol/L). Localisation diagnostic with ultrasound and 99mTc-sestamibi scintigraphy/SPECT/CT was inconclusive. Further imaging with an FCH-PET/CT localised a central necrotic, ectopic parathyroid gland within the right superior mediastinum (figure 3). The patient underwent thoracoscopic exploration of the mediastinum with complete resection of the hyperfunctioning parathyroid tissue which was classified as an adenoma in the histopathological work-up.
Figure 3.
18F-fluorocholine PET/CT in patient 2. Diagnostic-enhanced contrast CT (left) and PET (right) showing the adenoma located in the right superior mediastinum (arrow). Due to central necrosis within the adenoma, there is only low choline uptake (maximum standardised uptake value 3.5). PET, positron emission tomography.
Outcome and follow-up
Immediate and long-term postoperative calcium levels remained within the normal range. The first follow-up of both patients was 6 months postoperative. Further regular controls are also planned.
Discussion
Preoperative evaluation of patients with pHPT who are candidates for surgery includes cervical ultrasound and 99mTc-sestamibi scintigraphy/SPECT/CT to optimise tumour localisation, avoid unnecessary bilateral neck exploration and minimise surgical complications. However, sensitivity of both localisation procedures is reduced in patients with multiglandular disease, multinodular goitre or with ectopic localisation of the adenoma.10 11
In 2013, Quak et al 12 first described the incidental diagnosis of a parathyroid adenoma by FCH-PET/CT in a patient with prostate cancer. In the following years, small case series showed that FCH-PET/CT is a very sensitive diagnostic tool with—compared with scintigraphy/SPECT—equal or even better diagnostic accuracy.13–15 In selected cases, FCH-PET/CT can be useful for definitive diagnosis in patients with equivocal or negative sonographic and scintigraphic findings.
Compared with scintigraphy and SPECT, PET offers better spatial resolution, a better lesion to background ratio and can be easily combined with a diagnostic CT to provide the surgeon with important anatomical information. With optimised PET/CT protocols, radiation doses of FCH-PET/CT are comparable to sestamibi scintigraphy/SPECT/CT (approximately 8 mSv).16 17 At our clinic, costs of FCH-PET/CT are about double the costs of 99mTc-sestamibi SPECT/CT (CHF2874 compared with CHF1464, respectively; €3391 compared with €1727, respectively). However, image acquisition time of FCH-PET/CT is much shorter and less complicated (one examination phase of 20 min after an hour of uptake waiting time). For acquisition of 99mTc-sestamibi SPECT/CT, a dual phase is needed: a first examination of 10 min duration after 15 min uptake waiting time and a second examination phase of 30 min duration after 2 hours uptake waiting time.
In our patients, imaging with FCH-PET/CT led to a correct localisation of an ectopic mediastinal parathyroid adenoma in both cases with subsequent surgical cure of the disease. In the second case, the use of FCH-PET/CT spared the patient an unnecessary bilateral neck exploration. In our opinion, FCH-PET/CT offers a promising new imaging modality in patients with negative/equivocal ultrasound and/or scintigraphy/SPECT findings and is especially helpful in patients with mediastinal parathyroid adenoma. Compared with 99mTc-sestamibi scintigraphy/SPECT/CT in particular, it shows superior imaging results with comparable radiation exposure. However, larger head-to-head studies, comparing different imaging methods are needed for the approval of FCH-PET/CT as a first-line parathyroid imaging in the future.
Learning points.
In primary hyperparathyroidism, proper localisation of all autonomic tissue is essential for focused parathyroidectomy, including detection of ectopic and supernumerous parathyroid lesions.
First-line diagnostic imaging includes ultrasound of the neck and parathyroid scintigraphy with technetium (99mTc)-sestamibi (most often combined with single-photon emission CT (SPECT)/CT).
18F-fluorocholine (FCH)-PET/CT shows equal or even superior detection of ectopic parathyroid adenomas in the mediastinum and negative/equivocal conventional imaging procedures. Replacement of 99mTc-sestamibi scintigraphy/SPECT/CT by FCH-PET/CT as a first-line parathyroid imaging modality could be possible in the near future.
Footnotes
Contributors: SF and MT both contributed equally as main authors of this manuscript. They were also responsible for the literature research. SF was the supervising author of the manuscript. KS and AL reviewed the manuscript and made their comments as specialists of nuclear medicine (KS) and as the operating cardiothoracic surgeon (AL). KS also provided figures 1 and 3 and AL provided figure 2.
Competing interests: None declared.
Patient consent: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
References
- 1. Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg 1992;215:300–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Roy M, Mazeh H, Chen H, et al. Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg 2013;37:102–6. 10.1007/s00268-012-1773-z [DOI] [PubMed] [Google Scholar]
- 3. Nawrot I, Chudziński W, Ciąćka T, et al. Reoperations for persistent or recurrent primary hyperparathyroidism: results of a retrospective cohort study at a tertiary referral center. Med Sci Monit 2014;20:1604–12. 10.12659/MSM.890983 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Marcocci C, Bollerslev J, Khan AA, et al. Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607–18. 10.1210/jc.2014-1417 [DOI] [PubMed] [Google Scholar]
- 5. Johnson NA, Carty SE, Tublin ME. Parathyroid imaging. Radiol Clin North Am 2011;49:489–509. 10.1016/j.rcl.2011.02.009 [DOI] [PubMed] [Google Scholar]
- 6. Kluijfhout WP, Vorselaars WM, van den Berk SA, et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun 2016;37:1246–52. 10.1097/MNM.0000000000000595 [DOI] [PubMed] [Google Scholar]
- 7. Hocevar M, Lezaic L, Rep S, et al. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-fluorocholine PET/CT. Eur J Surg Oncol 2017;43:133–7. 10.1016/j.ejso.2016.09.016 [DOI] [PubMed] [Google Scholar]
- 8. Treglia G, Sadeghi R, Schalin-Jäntti C, et al. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: a meta-analysis. Head Neck 2016;38(Suppl 1):E2159–E2172. 10.1002/hed.24027 [DOI] [PubMed] [Google Scholar]
- 9. Kluijfhout WP, Pasternak JD, Gosnell JE, et al. 18F fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology 2017;284:460–7. 10.1148/radiol.2016160768 [DOI] [PubMed] [Google Scholar]
- 10. Cheung K, Wang TS, Farrokhyar F, et al. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012;19:577–83. 10.1245/s10434-011-1870-5 [DOI] [PubMed] [Google Scholar]
- 11. Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism-an evidence-based analysis. Langenbecks Arch Surg 2009;394:765–84. 10.1007/s00423-009-0534-4 [DOI] [PubMed] [Google Scholar]
- 12. Quak E, Lheureux S, Reznik Y, et al. F18-choline, a novel PET tracer for parathyroid adenoma? J Clin Endocrinol Metab 2013;98:3111–2. 10.1210/jc.2013-2084 [DOI] [PubMed] [Google Scholar]
- 13. Michaud L, Burgess A, Huchet V, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?. J Clin Endocrinol Metab 2014;99:4531–6. 10.1210/jc.2014-2821 [DOI] [PubMed] [Google Scholar]
- 14. Lezaic L, Rep S, Sever MJ, et al. 18F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 2014;41:2083–9. 10.1007/s00259-014-2837-0 [DOI] [PubMed] [Google Scholar]
- 15. Michaud L, Balogova S, Burgess A, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine 2015;94:e1701 10.1097/MD.0000000000001701 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002;43:92–6. [PubMed] [Google Scholar]
- 17. Mettler FA, Huda W, Yoshizumi TT, et al. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248:254–63. 10.1148/radiol.2481071451 [DOI] [PubMed] [Google Scholar]


